Reduced graphene oxide (rGO) has been studied as a resistive ammonia gas sensor at room temperature. The sensitive hybrid material composed of rGO and nano-silver ink (Ag-ink) was loaded on a microstrip patch antenna to realize high-performance wireless ammonia sensors. The material was investigated using scanning electron microscopy (SEM) and X-ray photoelectron spectroscopy (XPS). Firstly, interdigital electrodes (IDEs) printed on the polyethylene terephthalate (PET) by direct printing were employed to measure the variation of resistance of the sensitive material with the ammonia concentration. The results indicated the response of sensor varied from 4.25% to 14.7% under 15–200 ppm ammonia concentrations. Furthermore, the hybrid material was loaded on a microstrip patch antenna fabricated by a conventional printed circuit board (PCB) process, and a 10 MHz frequency shift of the sensor antenna could be observed for 200 ppm ammonia gas. Finally, the wireless sensing property of the sensor antenna was successfully tested using the same emitted antenna outside the gas chamber with a high gain of 5.48 dBi, and an increased reflection magnitude of the emitted antenna due to the frequency mismatch of the sensor antenna was observed. Therefore, wireless ammonia gas sensors loaded on a patch antenna have significant application prospects in the field of Internet of Things (IoTs).
AimsHetrombopag olamine is a novel small‐molecule, nonpeptide thrombopoietin receptor agonist developed for immune thrombocytopenia treatment. This study aims to determine the safety and the effect of fasting duration after administration of hetrombopag on pharmacokinetics and pharmacodynamics in Chinese healthy subjects.MethodsA randomized, open‐label, single‐dose, 3‐period crossover, self‐control trial was conducted. 15 eligible subjects were enrolled and received hetrombopag 7.5 mg at day 1 of each period followed by a standard meal 4 hours postdose (treatment A/fasting condition), or a high‐calorie, high‐fat meal 1 hour postdose (treatment B), or a high‐calorie, high‐fat meal 2 hours postdose (treatment C). The plasma concentrations of hetrombopag were determined by validated liquid chromatography–tandem mass spectrometry, platelet counts were quantified by blood test. Analysis was performed using a mixed model, including treatment, period as fixed effects and participant as a random effect.ResultsCompared with treatment A, peak concentration and area under concentration–time curve extrapolated to infinity decreased by 56 and 74.6%, and 44 and 61% in treatments B and C, respectively. The mean platelet number on day 6 increased by 15.8, 6.96 and 10.26%, respectively, in treatments A, B and C in comparison with baseline platelet level. No severe adverse events happened in any of the 3 treatments.ConclusionHetrombopag was well tolerated in healthy male subjects under fasted/fed conditions. The shorter fasting duration resulted in lower hetrombopag exposure, corresponding to a lower level of platelet elevation. Therefore, we recommended oral administration of hetrombopag on an empty stomach (fasting condition) or at least 2 hours before a meal to achieve maximum bioavailability.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.